Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2018; 118(03): 451-460
DOI: 10.1055/s-0038-1624581
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency

Manuel Carcao
1   Division of Haematology/Oncology and Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Canada
,
Carmen Altisent
2   Haemophilia Unit, Vall d'Hebron University Hospital, Barcelona, Spain
,
Giancarlo Castaman
3   Department of Oncology, Careggi University Hospital, Center for Bleeding Disorders and Coagulation, Firenze, Italy
,
Katsuyuki Fukutake
4   Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan
,
Bryce A. Kerlin
5   Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, Ohio, United States
,
Craig Kessler
6   Georgetown University Medical Center, Washington, DC, United States
,
Riitta Lassila
7   Coagulation Disorders Unit, Hematology and Comprehensive Cancer Center, University of Helsinki, Helsinki University Hospital, Helsinki, Finland
,
Diane Nugent
8   Center for Inherited Blood Disorders and UC Irvine Medical School, Children's Hospital of Orange County, Orange, California, United States
,
Johannes Oldenburg
9   Institute for Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
,
May-Lill Garly
10   Medical & Science, Biopharm, Global Development, Novo Nordisk A/S, Søborg, Denmark
,
Anders Rosholm
11   Biostatistics, Biopharm, Global Development, Novo Nordisk A/S, Søborg, Denmark
,
Aida Inbal
12   Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
› Author Affiliations
Further Information

Publication History

21 September 2017

11 December 2017

Publication Date:
15 February 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Recombinant factor XIII-A2 (rFXIII-A2) was developed for prophylaxis and treatment of bleeds in patients with congenital FXIII A-subunit deficiency. mentor™2 (NCT00978380), a multinational, open-label, single-arm, multiple-dosing extension to the pivotal mentor™1 trial, assessed long-term safety and efficacy of rFXIII-A2 prophylaxis in eligible patients (patients with severe [<0.05 IU/mL] congenital FXIII subunit A deficiency) aged ≥6 years. Patients received 35 IU/kg rFXIII-A2 (exact dosing) every 28 ± 2 days for ≥52 weeks. Primary endpoint was safety (adverse events including immunogenicity); secondary endpoints were rate of bleeds requiring FXIII treatment, haemostatic response after one 35 IU/kg rFXIII-A2 dose for breakthrough bleeds and withdrawals due to lack of rFXIII-A2 efficacy. Steady-state pharmacokinetic variables were also summarized. Elective surgery was permitted during the treatment period. Sixty patients were exposed to rFXIII-A2; their median age was 26.0 years (range: 7.0–77.0). rFXIII-A2 was well tolerated without any safety concerns. No non-neutralizing or neutralizing antibodies (inhibitors) against FXIII were detected. Mean annualized bleeding rate (ABR) was 0.043/patient-year. Mean spontaneous ABR was 0.011/patient-year. No patients withdrew due to lack of efficacy. Geometric mean FXIII trough level was 0.17 IU/mL. Geometric terminal half-life was 13.7 days. rFXIII-A2 prophylaxis provided sufficient haemostatic coverage for 12 minor surgeries without the need for additional FXIII therapy; eight procedures were performed within 7 days of the patient's last scheduled rFXIII-A2 dose, and four were performed 10 to 21 days after the last dose.

Keywords

recombinant FXIII-A2 - safety - congenital FXIII deficiency - prophylaxis - surgery

Financial Support

This trial was sponsored by Novo Nordisk A/S (Bagsværd, Denmark).


Author Contributions

M.-L. Garly and A. Rosholm: representing Novo Nordisk A/S study concept and protocol. A. Rosholm: statistical analyses. M. Carcao, C. Altisent, G. Castaman, K. Fukutake, B. Kerlin, C. Kessler, R. Lassila, D. Nugent, J. Oldenburg and A. Inbal: data acquisition. M. Carcao, C. Altisent, G. Castaman, K. Fukutake, B. Kerlin, C. Kessler, R. Lassila, D. Nugent, J. Oldenburg, M.-L. Garly, A. Rosholm and A. Inbal: analysis and interpretation of data. M. Carcao: manuscript drafting. M. Carcao, C. Altisent, G. Castaman, K. Fukutake, B. Kerlin, C. Kessler, R. Lassila, D. Nugent, J. Oldenburg, M.-L. Garly, A. Rosholm and A. Inbal: critical revision and final draft of manuscript.


 

  • References

  • 1 Chung SI, Lewis MS, Folk JE. Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures. J Biol Chem 1974; 249 (03) 940-950
    PubMedGoogle Scholar
  • 2 Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248 (04) 1395-1407
    PubMedGoogle Scholar
  • 3 Muszbek L, Katona É. Diagnosis and Management of Congenital and Acquired FXIII Deficiencies. Semin Thromb Hemost 2016; 42 (04) 429-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Peyvandi F, Palla R, Menegatti M. , et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
    CrossrefPubMedGoogle Scholar
  • 5 Anwar R, Minford A, Gallivan L, Trinh CH, Markham AF. Delayed umbilical bleeding—a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109 (02) E32
    CrossrefPubMedGoogle Scholar
  • 6 Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol 2016; 95 (03) 451-455
    CrossrefPubMedGoogle Scholar
  • 7 Janbain M, Nugent DJ, Powell JS, St-Louis J, Frame VB, Leissinger CA. Use of factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures. Transfusion 2015; 55 (01) 45-50
    CrossrefPubMedGoogle Scholar
  • 8 Ivaskevicius V, Seitz R, Kohler HP. , et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14 (06) 1190-1200
    CrossrefPubMedGoogle Scholar
  • 10 European Medicines Agency EMA. 2011. Guideline on plasma-derived medicinal products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109627.pdf . Accessed October 11, 2016
    PubMedGoogle Scholar
  • 11 European Medicines Agency EMA. 2012. European Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002284/WC500132997.pdf . Accessed December 6, 2016
    PubMedGoogle Scholar
  • 12 Dorey E. First recombinant factor XIII approved. Nat Biotechnol 2014; 32 (03) 210
    PubMedGoogle Scholar
  • 13 Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. ; Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9 (07) 1404-1406
    CrossrefPubMedGoogle Scholar
  • 14 Lovejoy AE, Reynolds TC, Visich JE. , et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108 (01) 57-62
    CrossrefPubMedGoogle Scholar
  • 15 Mumford AD, Ackroyd S, Alikhan R. , et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
    CrossrefPubMedGoogle Scholar
  • 16 Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14 (04) 671-684
    CrossrefPubMedGoogle Scholar
  • 17 Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119 (22) 5111-5117
    CrossrefPubMedGoogle Scholar
  • 18 Kerlin BA, Inbal A, Will A. , et al. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results. J Thromb Haemost 2017; 15 (08) 1601-1606
    CrossrefPubMedGoogle Scholar
  • 19 Williams M, Will A, Stenmo C, Rosholm A, Tehranchi R. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients. Haemophilia 2014; 20 (01) 99-105
    PubMedGoogle Scholar
  • 20 Brand-Staufer B, Carcao M, Kerlin BA. , et al. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency. Haemophilia 2015; 21 (03) 380-385
    CrossrefPubMedGoogle Scholar
  • 21 Carcao M, Fukutake K, Inbal A. , et al. Developing the first recombinant factor XIII for congenital factor XIII deficiency: clinical challenges and successes. Semin Thromb Hemost 2017; 43 (01) 59-68
    PubMedGoogle Scholar
  • 22 Kerlin B, Brand B, Inbal A. , et al. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. J Thromb Haemost 2014; 12 (12) 2038-2043
    CrossrefPubMedGoogle Scholar
  • 23 Food and Drug Administration FDA. 2016. Electronic Code of Federal Regulations 312.120. Available at: http://www.ecfr.gov/cgi-bin/text-idx?SID=3ee286332416f26a91d9e6d786a604ab&mc=true&tpl=/ecfrbrowse/Title21/21tab_02.tpl . Accessed February 2, 2016
    PubMedGoogle Scholar
  • 24 International Conference Harmonisation ICH. 2016. Tripartite Harmonised Guideline: Good Clinical Practice, Consolidated Guideline (E6). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf . Accessed February 2, 2016
    PubMedGoogle Scholar
  • 25 World Medical Association WMA. 2016. Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ . Accessed February 2, 2016
    PubMedGoogle Scholar
  • 26 Solomon C, Korte W, Fries D. , et al. Safety of factor XIII concentrate: analysis of more than 20 years of pharmacovigilance data. Transfus Med Hemother 2016; 43 (05) 365-373
    CrossrefPubMedGoogle Scholar
  • 27 Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16 (02) 316-321
    CrossrefPubMedGoogle Scholar
  • 28 Ashley C, Chang E, Davis J, Mangione A, Frame V, Nugent DJ. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency. Haemophilia 2015; 21 (01) 102-108
    CrossrefPubMedGoogle Scholar
  • 29 Árokszállási A, Kerényi A, Katona É. , et al. The use of recombinant factor XIII in a major bleeding episode of a patient with congenital factor XIII deficiency–the first experience. Haemophilia 2015; 21 (01) e118-e121
    CrossrefPubMedGoogle Scholar
  • 30 World Federation of Haemophilia. Report on Annual Global Survey 2014. Available at: http://www1.wfh.org/publications/files/pdf-1627.pdf . Accessed February 2, 2016
    PubMedGoogle Scholar